Every material Form 8-K Kardigan, Inc. has filed with the SEC since November 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Kardigan said it completed enrollment in its Phase 2b KATALYST-AV trial of ataciguat in aortic stenosis, with 156 participants enrolled. It amended the protocol to assess the primary endpoint of aortic valve calcium at Week 48 instead, and the press release now puts topline data in the second half of 2027, which means a longer wait for shareholders.
156 participants enrolled in KATALYST-AV; baseline data from the first 139 were analyzed
Primary endpoint of aortic valve calcium moved to Week 48; an internal interim analysis is planned for Week 24
Press release gives topline data timing as second half of 2027, while the 8-K item text says second half of 2026
Investor webcast at the American Heart Association meeting on November 7, 2026, at 8:00 AM ET
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Kardigan, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →